Drug General Information (ID: DDINTI8G95)
Drug Name			Paricalcitol		Drug Info		Erdafitinib		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Parasympathomimetics				Multikinase Inhibitors
Structure

Mechanism of Paricalcitol-Erdafitinib Interaction (Severity Level: Major)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Paricalcitol				Erdafitinib
Mechanism		Hyperphosphatemia				Titration affected by phosphate levels
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Erdafitinib when combined with Paricalcitol

Recommended Action
Management		The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels. After the initial dose increase period, an oral phosphate binder may be appropriate in the management of patients with serum phosphate levels greater than 7 mg/dL. If concomitant use with agents known to increase serum phosphate levels is required after this initial dose increase period, close monitoring of patient tolerability and serum phosphate levels is recommended.

References
1	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.